Cohesive corporate advice across jurisdictions

Our international corporate team has the capability, resources and experience to manage transactions efficiently and quickly. Our relationship-driven approach means that when you work with us, you'll benefit from our market intelligence, specialist industry knowledge and commercial business solutions. With specialists in all areas of corporate law, we're known for being a strong mid-market player that is pushing into larger transactions.

"All of our matters cut across jurisdictions, yet Osborne Clarke deals with them in a clear and concise manner."

Corporate/M&A: £100-800 million client, Chambers and Partners

How we can help you

Our experts can advise on all aspects of your company's journey, helping you make the most of opportunities and challenges. The core of our work is M&A, venture and private equity. Many of our clients come to us for domestic work, as well as domestically generated work with international cross-border dimensions. We have a deep specialism in advising on inbound European transactions.

Legal tech solutions

We also use technology and various AI services to deliver deal efficiency and cost-effectiveness. OC Solutions provides a single source of truth to manage corporate transactions. It brings all of the deal information together in one intuitive location. This means that when you work with us, you will have real-time deal data at your fingertips.

"Osborne Clarke provide expert and clear advice based on a deep understanding of the commercial and legal issues. The strength and depth of their teams is evident across the firm; technical expertise combined with strong commercial awareness and good interpersonal skills."

Corporate Client, Legal 500

Our international corporate lawyers

We have corporate lawyers in the UK, Germany, France. Italy, Poland, Sweden, Spain. the US, The Netherlands, Belgium, Singapore and China. They work together to provide cohesive advice across Europe, the US and Asia.

Our portfolio of clients includes fast-growing businesses and those with a tech focus. We are the legal advisor of choice for future-focused clients and organisations at the forefront of innovation and transformation in their market. We work across a range of sectors, including tech, media and comms, financial services, real estate, life sciences and healthcare.

Experience

BioNTech

Advised German immunotherapies developer and manufacturer BionTech on its acquisition of pioneering AI-powered drug discovery and development company InstaDeep.

Brompton

Advised Brompton on a £19m investment by BGF and other shareholders.

Nutrisure

Advised on the investment in Nutrisure by Lonsdale Capital.

Lloyds Development Capital

Advised on the £140m AIM IPO of Joules Group plc.

Investec Bank

Advised on on the £50m AIM IPO of Blue Prism Group plc.

Cantor Fitzgerald Europe

Advised on the £70m AIM IPO of Stride Gaming plc.

FeverTree Drinks plc

Advised on its £154m AIM IPO.

Chamartín Meermann Immobilien AG

Advised on  its €80m IPO on the Frankfurt Stock Exchange.

Media[netCom] AG

Advised on its €40m IPO on the Frankfurt Stock Exchange.

Tribal Group plc

Advised on its £42m rights issue, disposal of its Synergy business and move to AIM.

Investec Bank

Advised on the £20m placing by Johnson Services Group plc.

Canaccord Genuity

Advised on the £18m placing by Goals Soccer Centres plc.

Panmure Gordon

Advised on the reverse takeover of Eclectic Bar Group plc.

UNITE Group plc

Advised on its £100m placing and open offer.

Bridges Ventures LLP

Advised on the formation of Bridges Property Alternatives Funds III (2015) and IV (2016).

Foresight Group LLP

Advised on the launch of its second regional investment fund, an LP fund targeting £60m in commitments for private equity investment into the North West of England, with the backing of various local government pension schemes in the region.

Niam

Advised on all aspects of structuring and establishment of the Niam Nordic VI closed-ended real estate fund with equity commitments of €800 million.

Carphone Warehouse

Worked to establish a £2.2 billion joint venture with American retailer Best Buy, and later worked to unwind the venture when Carphone Warehouse bought out its partner.

SNCF

Advised Ermewa, the freight asset management subsidiary of SNCF, the French national rail operator, on its sale of 50% of the shares of its wholly-owned locomotive operator Akiem to Deutsche Asset & Wealth Management, allowing Akiem to improve its fleet and expand further.

British Waterways and Canary Wharf Group

Helped the two companies establish the Wood Wharf Limited Partnership, which opened up land in London’s Canary Wharf to new development.

NoHo Film and ITV

Advised on the formation of a joint venture TV production backed by ITV Studios, one of the UK’s largest television production companies.

Blue-ng

Advised a joint venture between National Grid and 20C on its projects to exploit renewable energy in the natural gas transmission network.

Acano

Advised online collaboration business Acano on its $700m acquisition by Cisco systems.

Cloud Talent

Advised strategic cloud consulting business Cloud Talent on its sale to Avanade.

Iris Worldwide

Advised international agency networki on its sale to Cheil Worldwide, Inc.

ByBox

Advised the selling shareholders and management team on the auction sale process leading to an MBO backed by LDC who invested £37.5m alongside £55m of senior debt provided by RBS valuing the business at £105m.

IDScan

Advised fintech business IDScan on its £45m sale to GB Group Plc.

Time Inc

Advised Time Inc. (UK) on their acquisition of digital creative advertising business, Collective Europe Limited from Collective Inc.

Majestic Wine

Advised Majestic Wine on its £70m acquisition of Naked Wine.

Rotork

Advised Rotork on its acquisition of the Bifold Group Ltd from private equity house LDC for up to £125m on a cash-free, debt-free basis.

Actavis UK and Acatvis Ireland

Advised Actavis UK Limited and Actavis Ireland Limited on its proposed £603m divestment by Teva Pharmaceutical Industries Ltd to Intas Pharmaceuticals Ltd.